Mesoblast (ASX:MSB) has appointed physician scientist Dr Teresa Montagut to lead its clinical development and medical affairs efforts, strengthening the company’s leadership team as it expands its portfolio of cell therapies for inflammatory diseases.
Cell therapy company Mesoblast names executive to guide clinical development and medical affairs
March 12, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News

